Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188179 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BALOX15TRPV1FPR2 | |
| Hydrochloric Acid SCHEMBL11454643 | 0.99 | ITGB3 (0.46) | ITGB3ITGA2BALOX15TRPV1FPR2 | |
| SCHEMBL1067908 | 0.89 | ALOX15 (0.46) | ALOX15TRPV1PTGS1 | |
| SCHEMBL11684066 | 0.88 | ALOX15 (0.47) | ALOX15TRPV1FPR2ALDH1A1LDHA | |
| SCHEMBL25471843 | 0.88 | ITGB3 (0.49) | ITGB3ITGA2BALOX15TRPV1FPR2 | |
| Hydrochloric Acid SCHEMBL11446868 | 0.88 | ALOX15 (0.45) | ALOX15TRPV1ALDH1A1PTGS1 | |
| SCHEMBL1069133 | 0.86 | ALOX15 (0.44) | ALOX15TRPV1ALDH1A1PTGS1CCR5 | |
| SCHEMBL1069784 | 0.86 | ALDH1A1 (0.44) | ITGB3ITGA2BALOX15FPR2ALDH1A1 | |
| SCHEMBL22290251 | 0.86 | HDAC3 (0.44) | ALOX15FPR2ALDH1A1LDHAKDM4E | |
| SCHEMBL1071712 | 0.86 | HDAC3 (0.44) | ALOX15FPR2ALDH1A1LDHAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | claimed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | claimed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | claimed |
| WO-2022190100-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2022-09-15 | — | — | WO | claimed |
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | claimed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | claimed |
| US-3961041-A | PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-06-01 | — | — | US | claimed |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | NEURODERM LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| EP-4460289-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | Neuroderm, Ltd. (IL) | 2024-11-13 | — | — | EP | disclosed |
| CN-118765198-A | Methods and compositions for treating parkinson's disease | 纽罗德姆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | NEURODERM, LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-30 | — | — | US | disclosed |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | Arizona Board of Regents, a body Corporate of the State of Arizona, acting for and on behalf of the (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2273988-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009129497-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS, A BODY CORP. OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-22 | — | — | WO | disclosed |
| US-4065566-A | PRO-DRUG FORM OF L-DOPA, PARKINSON*S DISEASE | INTERX RESEARCH CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3939253-A | Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | ITGB3 4534/4885ITGA2B 4447/4885ALOX15 395/4885 |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | MTNR1A, MC1R, MTNR1B | ITGB3 1582/4885ITGA2B 2433/4885ALOX15 674/4885 |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | PDE6C, AGER, PDE6D | ITGB3 1187/4885ITGA2B 1973/4885ALOX15 118/4885 |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | DDC, DDT, COMT | ITGB3 4765/4885ITGA2B 4791/4885ALOX15 1146/4885 |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | DDC, COMT, DDT | ITGB3 4748/4885ITGA2B 4797/4885ALOX15 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.